Pure Biologics S.A. (FRA:PQB)

Market Cap	6.71M -14.5%
Revenue (ttm)	n/a
Net Income	-2.50M
EPS	-0.37
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.4755
Previous Close	0.4540
Day's Range	0.4755 - 0.4755
52-Week Range	0.2432 - 1.8320
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Sep 30, 2026

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and medical devices for therapeutic use. Its therapeutic portfolio in the field of immuno-oncology includes PB003G, which targets the GARP-TGFβ1 complex; PB004, an anticancer drug based on an anti-ROR1 antibody; and PB003A, a therapy that targets the αVβ8 integrin. The company was founded in 2010 and is based in Wrocław, Poland.

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2010
• Employees: 7
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: PQB

Financial Performance

Financial numbers in PLN

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Jun 26, 2026

Data Sources Report a data error